265 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Exclude Unknown | Expanded Access Studies (265 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Available Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102
2 Approved for marketing A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
3 Available Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan
Condition: Prostate Cancer
Intervention: Drug: [11C]Acetate
4 Available Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Condition: Infection Due to Resistant Organism
Intervention: Drug: Arbekacin Sulfate
5 No longer available A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Condition: HIV
Intervention: Drug: Maraviroc
6 No longer available Erwinase Master Treatment Protocol
Conditions: Leukemia, Acute Lymphoblastic;   Acute Lymphoid Leukemia
Intervention: Drug: Erwinia L-asparaginase
7 Temporarily not available Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: R(+) pramipexole dihydrochloride monohydrate
8 Available Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Condition: Retinal Hemangioma
Intervention: Drug: Aflibercept
9 No longer available Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment
Condition: Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
Intervention: Behavioral: questionnaire
10 No longer available Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
Conditions: Hepatitis B;   Chronic Disease
Intervention: Drug: Entecavir
11 Approved for marketing Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
12 Approved for marketing Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
Condition: Autologous Stem Cell Transplant
Intervention: Drug: AMD3100 + G-CSF
13 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
14 Available Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
Condition: Malignant Solid Tumour
Intervention: Drug: SCB01A
15 Approved for marketing Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab
16 Available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Conditions: Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Biological: G-CSF mobilized CD34+ selected cells for transplantation
17 Approved for marketing Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis
Condition: Osteoarthritis of the Hand
Intervention: Drug: Diclofenac
18 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
19 No longer available Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: stiripentol
20 Approved for marketing Alglucosidase Alfa Temporary Access Program
Conditions: Glycogen Storage Disease Type II (GSD-II);   Pompe Disease (Late-Onset);   Acid Maltase Deficiency Disease;   Glycogenosis 2
Intervention: Biological: alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years